Plus   Neg

Vertex Pharmaceuticals Inc. (VRTX) Is Surging To A New High On Study Results

Vertex Pharmaceuticals Inc. (VRTX) announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis who have one F508del mutation and one minimal function mutation.

Vertex Pharmaceuticals has gapped open dramatically higher Wednesday morning and is now up 33.62 at $165.78. The stock has surged past the upper end of nearly a 1-month trading range and has set a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT